(United States Third Circuit) – Reversing the District Court dismissal of complaints in litigation that alleged Lipitor’s fraudulent patent procurement and other misconduct because the allegations were plausible, and reversing the dismissal of allegations in Effexor litigation because it was plausible that the companies holding the pharmaceutical patents and generic manufacturers entered into reverse payment settlement agreements that subjected them to antitrust scrutiny.